UK
Deal Maker of the Year Awards 2013 WINNER - HENRY TALBOT-PONSONBY
DEAL: North West Fund for Biomedical invests in TTS Pharma
NAME: Henry Talbot-Ponsonby COMPANY: VCP Advisors POSITION: Managing Partner ADDRESS:
TEL: +44 207 858 1299 DEAL OVERVIEW
VCP was retained by TTS Pharma Limited (TTS) as lead corporate finance adviser with a mandate to advise the company on raising investment funds. TTS is a pioneer in the personalised medicine arena: right drug to the right patient at the right dose. TTS’ proprietary IP allows the pharmacogenetic stratification of patients and thereby accurate prescriptive treatment. By targeting treatment to the patient, TTS is able to increase a treatment’s effectiveness, and thereby reduce the cost of its delivery. This gives TTS’ technology both an emerging and developed market appeal. Having identified the UK and China as the key initial markets for its products, it was essential that TTS built an investor base that was both comfortable with and supportive of the China plans. Working closely with TTS’ management team, VCP successfully raised capital from a number of private investors including the cornerstone investor, Spark Ventures’ North West Fund for BioMedical.
VCP’s success in the TTS transaction ❝ BIO
Henry is Managing Partner at VCP Advisors. He began his career as a Barrister having been called to the Bar by the Inner Temple. Following a move into investment banking, he worked with Grisons Peak, a corporate finance advisory firm focused on European mid-market financial institutions. From there, Henry founded Venture Capital Partners (VCP), a sector generalist advisory and capital raising firm focused on small and medium sized enterprises in Europe. VCP’s success was borne out of its ability to raise capital for its clients from its established network of institutions, family offices and ultra-high net worth individuals. In light of this success, VCP was able to expand its advisory services to private equity funds and hedge funds. To better reflect this more diverse service offering, the company rebranded to VCP Advisors. Headquartered in London, VCP Advisors has an office in Beijing, and is opening an office in New York in Q1 2014.
28 Eccleston Square London SW1V 1NZ
demonstrates its ability to raise capital from both institutional and ‘off the radar’ private investors. Through its close links to, and constant dialogue with, this network of family office and institutional investors, VCP builds a clear picture of the types of companies that investors are seeking. It then analyses the
market place to find the companies that best meet these strict criteria. With significant dry-powder held in investment funds across Europe, VCP sees huge demand for profitable, high growth companies and this is only set to increase as credit conditions continue to improve and the M&A market thaws.
By targeting treatment to the patient, TTS is able to increase a treatment’s effectiveness, and thereby reduce the cost of its delivery.
www.finance-monthly.com 61
❝
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102